OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer

June 30th 2025

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Dr Ansley on Inavolisib Plus Palbociclib/Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

June 30th 2025

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

Dr Huang on the Efficacy of Sintilimab Plus Chidamide and P-GemOx in Treatment-Naive ENKTL.

June 30th 2025

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Dr Wainberg on Phase 2 Domvanalimab/Zimberelimab/Chemo Data in Gastric Cancer

June 30th 2025

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Dr Arora on Findings From a SEER Database Analysis in Mantle Cell Lymphoma

June 30th 2025

Ruby Arora, MD, discusses findings from a SEER database analysis of mantle cell lymphoma incidence rates from 2000 to 2021.

Dr Scarfò on the Rationale for Evaluating BGB-16673 in Relapsed/Refractory CLL

June 30th 2025

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.

Dr Mouabbi on Developing Consensus Around Treatment De-Escalation in HER2+ Breast Cancer Following pCR

June 27th 2025

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

Dr Danilov on the Evolution of Chemotherapy-Free Treatment Options in MCL

June 27th 2025

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Dr El-Saghir on the Implications of the RIGHT Choice Trial of Ribociclib Plus ET in HR+, HER2– Advanced Breast Cancer

June 27th 2025

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Dr Shitara on the Unique Mechanisms of Action of Domvanalimab Plus Zimberelimab in GI Cancer

June 27th 2025

Kohei Shitara, MD, details the mechanisms of action of the investigational therapies domvanalimab and zimberelimab for gastrointestinal cancer.

Dr Kahl on the Evolving Role of BTK Inhibitors in MCL

June 27th 2025

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

Dr Halmos on Differentiating Neuroendocrine Tumors From Neuroendocrine Carcinomas

June 27th 2025

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

Dr Randall on the Evolving Role of Surgical Management in Low-Grade Chondrosarcoma

June 27th 2025

R. Lor Randall, MD, FACS discusses the evolving role of surgical management in patients with low-grade chondrosarcoma.

Dr Nagasaka on the Importance of Taletrectinib for the ROS1+ NSCLC Treatment Paradigm

June 27th 2025

Misako Nagasaka, MD, PhD, discussed the clinical significance of the FDA approval of taletrectinib in ROS1-positive NSCLC.

Dr Palandri on Outcomes With Momelotinib in Myelofibrosis Per Dual SVR35 and Transfusion Independence

June 27th 2025

Francesca Palandri, MD, shares SVR35 rates with momelotinib vs ruxolitinib across patient subgroups in the anemic subpopulation of SIMPLIFY-1.

Dr Reni on the Efficacy of Preoperative PAXG in Stage I to III PDAC

June 26th 2025

Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.

Dr Johnson on Treatment Gaps With Immunotherapy in Melanoma

June 25th 2025

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Dr Moser on the SUPRAME Trial of IMA203 in Pretreated Cutaneous Melanoma

June 25th 2025

Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

June 25th 2025

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Dr McCann on the Importance of Reaching Consensus on the Role of Vepdegestrant in ER+ Breast Cancer

June 25th 2025

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.